Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001508985 | SCV001715449 | uncertain significance | not provided | 2021-01-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001865950 | SCV002117369 | uncertain significance | RASopathy | 2025-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 431 of the SOS1 protein (p.Gly431Ser). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SOS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1163704). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SOS1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV002468257 | SCV002763437 | uncertain significance | Noonan syndrome 4 | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV002468256 | SCV002763438 | uncertain significance | Fibromatosis, gingival, 1 | criteria provided, single submitter | clinical testing | ||
Ambry Genetics | RCV005278868 | SCV005947550 | uncertain significance | Cardiovascular phenotype | 2025-01-10 | criteria provided, single submitter | clinical testing | The p.G431S variant (also known as c.1291G>A), located in coding exon 10 of the SOS1 gene, results from a G to A substitution at nucleotide position 1291. The glycine at codon 431 is replaced by serine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |